J&J Settles Risperdal Marketing Claims From DOJ, States

Law360, New York (August 2, 2012, 9:46 PM EDT) -- Johnson & Johnson has settled claims brought by the U.S. Department of Justice and several states that it illegally marketed its antipsychotic drug Risperdal, as well as False Claims Act and Medicaid-related allegations, according to a securities filing issued Thursday.

The agreement will resolve claims made in the Eastern District of Pennsylvania surrounding Johnson & Johnson’s marketing of Risperdal and schizophrenia drug Invega, according to the U.S. Securities and Exchange Commission filing. It will also settle suits in California over its marketing of heart failure drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.